Skip to main content
padlock icon - secure page this page is secure

Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody-Drug Conjugates and Degradation Agents

Buy Article:

$68.00 + tax (Refund Policy)

Microtubules are essential for the mitotic division of cells and have been an attractive target for antitumour drugs due to the increased incidence of cancer and significant mitosis rate of tumour cells. In the past few years, tubulin-colchicine binding site, as one of the three binding pockets including taxol-, vinblastine- and colchicine-binding sites, has been focused on to design tubulin-destabilizing agents including inhibitors, antibody-drug conjugates and degradation agents. The present review is the first to cover a systemic and recent synopsis of tubulin-colchicine binding site agents. We believe that it would provide an increase in our understanding of receptor-ligand interaction pattern and consciousness of a series of challenges about tubulin target druggability.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antibody-drug conjugates; Antimitotic; Antitumour; Degraders; Inhibitors; Microtubules; Tubulin-colchicine binding site

Document Type: Review Article

Publication date: June 1, 2019

This article was made available online on July 10, 2019 as a Fast Track article with title: "Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents".

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more